US FDA reinspection outcome uncertain
The warning letter period ends in two weeks; reinspection timing and outcome are unknown, posing a risk to pharma recovery.
HIKAL / bear-case history
Track the concerns that keep returning.
Hikal · risk themes across the available quarters.
Research layer active
Bear-case history
Risks carried through the record.
high
Persistent crop pricing pressure from China
Chinese overcapacity continues to pressure crop protection pricing and margins, with no near-term relief expected.
Revenue reversal adjustment may raise questions
An ₹80 crore revenue reversal from Q2 was adjusted in Q3; ongoing system review could imply further adjustments, though management denies this.
Animal health volume ramp-up slower than expected
Animal health commercial volumes are still ramping; full utilization may not be reached until FY28, delaying revenue contribution.
USFDA warning letter resolution delay
USFDA warning letter at Bangalore site continues to impact CDMO growth and new customer onboarding. Management expects resolution by end of FY27 but timeline uncertain.
Raw material cost inflation and pass-through lag
Solvent prices have surged due to geopolitical tensions; pass-through mechanisms have a lag of one quarter, potentially impacting Q1 FY27 margins.
Impairment of multipurpose agrochemical facility
Company took a ₹47 crore impairment on a multipurpose agrochemical plant being retooled for pharma, indicating past capex inefficiencies.